Transenterix Inc (NYSEAMERICAN:TRXC) was the recipient of a significant increase in short interest in December. As of December 29th, there was short interest totalling 15,231,489 shares, an increase of 4.6% from the December 15th total of 14,554,764 shares. Approximately 10.4% of the company’s stock are sold short. Based on an average daily trading volume, of 2,743,340 shares, the days-to-cover ratio is currently 5.6 days.
In related news, CFO Joseph P. Slattery sold 333,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $2.93, for a total transaction of $975,690.00. Following the transaction, the chief financial officer now directly owns 440,974 shares in the company, valued at $1,292,053.82. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Joseph P. Slattery sold 529,609 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $2.80, for a total transaction of $1,482,905.20. Following the transaction, the chief financial officer now owns 440,974 shares in the company, valued at $1,234,727.20. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Transenterix stock. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 79,150 shares of the medical instruments supplier’s stock after buying an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned about 0.05% of Transenterix worth $113,000 as of its most recent filing with the Securities & Exchange Commission.
Several equities research analysts recently weighed in on the stock. Ladenburg Thalmann Financial Services set a $5.00 price objective on shares of Transenterix and gave the stock a “buy” rating in a research report on Friday, October 20th. Stifel Nicolaus reissued a “buy” rating and issued a $4.00 target price (up previously from $3.75) on shares of Transenterix in a report on Monday, October 30th. BTIG Research reaffirmed a “hold” rating on shares of Transenterix in a research note on Monday, December 18th. Finally, Zacks Investment Research downgraded Transenterix from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Transenterix currently has an average rating of “Hold” and an average target price of $2.61.
Shares of Transenterix (NYSEAMERICAN TRXC) opened at $1.65 on Friday. The firm has a market cap of $346.68, a P/E ratio of -2.66 and a beta of 2.02. Transenterix has a 52-week low of $0.45 and a 52-week high of $5.00.
Transenterix (NYSEAMERICAN:TRXC) last released its earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Transenterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%.
COPYRIGHT VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/02/transenterix-inc-trxc-sees-large-increase-in-short-interest.html.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.